Microchip detects type and severity of cancer 

In 2007, Dr. Shana Kelley, new to prostate cancer research, submitted a grant proposal to Prostate Cancer Canada requesting financial support for her project. “Prostate Cancer Canada was the first organization to sponsor my research. The $60,000 grant received from PCC enabled me to obtain the additional funds from other sources required to complete my experiments”, says Dr. Kelley. What was described as a new strategy for the detection of prostate cancer, Dr. Kelley’s application was one of over 60 applications received and reviewed by Prostate Cancer Canada’s Scientific and Medical Advisory Committee. 
Dr. Kelley’s proposal described a new strategy for the detection of prostate cancer based on an inexpensive approach, enabling routine testing in the doctor’s office. She and her colleagues were attempting to develop a quick and convenient new tool using microchips for detecting new markers of prostate cancer. By using a microchip that is programmed to detect DNA sequences produced by specific cancers or pathogens, patients will simply have to provide a sample (urine or blood) put it on the chip and allow the chip reader to analyze it. 
Dr. Kelley recently announced that the tool she and her team had been working on since 2007 had successfully detected prostate cancer markers in clinical biopsy samples. The results of her team’s research should give doctors the ability to determine the severity of tumors through a simple urine or blood sample and produce a quick diagnosis with no need for invasive and uncomfortable procedures, such as biopsies. This device is expected to be used in doctor’s offices within approximately five years.

View Dr. Kelley's CBC interview with Peter Mansbridge:
"Manbridge One on One"

View original press release from the University of Toronto here.

Donate Now!

Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.

Prostate Cancer Canada launches first national program in radioligand therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.

Click here for news archive